Expansion of the CDMO business through the acquisition of API Corporation
First written in FY2023-Q1. 2 of 6 entries say "Achieved", first in FY2023-Q3. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025AchievedAnnual report
「Based on a resolution of its Board of Directors dated 21 December 2023, the Company completed an absorption-type merger with its wholly owned subsidiary エーピーアイコーポレーション, effective 1 December 2024.」
As the next step following the acquisition of APIC, the absorption-type merger with the Company was completed on 1 December 2024, achieving full integration of the CDMO business. - FY2024AdvancedAnnual report
「In the CDMO business, the Company aims to maximize earnings at the Fifth Pharmaceutical Plant, a facility for manufacturing small-volume, highly potent active pharmaceutical ingredients, and achieve full integration and more efficient business operations through the absorption-type merger of エーピーアイコーポレーション.」
As the next step following the APIC acquisition, a plan was presented to achieve full integration and more efficient business operations through an absorption-type merger. - FY2024-Q2RestatedAnnual report
「The Pharmaceuticals business reported higher revenue, benefiting from the acquisition in December last year of ㈱エーピーアイコーポレーション, a contract pharmaceutical manufacturing company.」
The effect of the APIC acquisition emerged as increased revenue in the pharmaceuticals business even in the cumulative second-quarter results, reconfirming the effect of expanding the CDMO business after the acquisition. - FY2024-Q1RestatedAnnual report
「The Pharmaceuticals business reported higher revenue, benefiting from the acquisition in December last year of ㈱エーピーアイコーポレーション, a contract pharmaceutical manufacturing company.」
Following completion of the acquisition of APIC in December 2022, its effect was confirmed in the form of increased revenue in the pharmaceuticals business. - FY2023-Q3AchievedAnnual report
「Business combination date 1 December 2022 (share acquisition date) 31 December 2022 (deemed acquisition date) Voting rights ratio after acquisition: 100%」
The acquisition of APIC was completed on 1 December 2022, making it a consolidated subsidiary with a 100% voting rights ratio after the acquisition. The acquisition consideration was provisionally calculated at ¥5,400 million, with provisional goodwill of ¥445 million. - FY2023-Q1First statedAnnual report
「At a meeting of its Board of Directors held on 4 August 2022, the Company resolved to acquire all shares of エーピーアイコーポレーション, held by Life Science Institute Co., Ltd., a member of the Mitsubishi Chemical Group, and entered into a share transfer agreement on the same date. To meet demand in the CDMO market, which is expected to continue expanding, the transaction aims to strengthen the Company’s presence in the market by establishing a high-quality, stable supply structure through the mutual use of the two companies’ advanced manufacturing and quality-control technologies, joint development of new technologies, expansion of their supply-chain networks and use of their respective sites. Number of shares to be acquired: 5,488 Ownership after acquisition: 100% Timing of share acquisition: Scheduled for December 2022」
The Company resolved to acquire all shares of APIC and entered into a share transfer agreement. Completion of the acquisition was scheduled for December 2022, with the transaction aimed at strengthening the pharmaceuticals business through the mutual use of manufacturing and quality-control technologies, joint development and supply-chain expansion in the CDMO market.